Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472030 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00472030: Completed Phase 4 study, sponsored by University of Iowa.
NCT00472030 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00472030, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study. Patients treated with Xolair will be compared to patients receiving standard treatment with prednisone. The enrollment period for the study is 24 weeks: 16 weeks active treatment and 8 additional weeks of observation.
Primary Outcome
The study subject underwent physical examination and was assessed for cessation of new blister formation via physical examination and photography.
Interventions
- DRUG prednisone
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
What the finished NCT00472030 record still lists
NCT00472030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00472030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00472030 about?
NCT00472030 is a clinical study titled "Efficacy and Safety of Omalizumab in Bullous Pemphigoid". The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study. Patients treated with Xolair will be compared to patients receiving standard treatment with prednisone. ...
What is the current status of trial NCT00472030?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2007-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00472030?
The interventions under investigation include: prednisone (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00472030?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00472030's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia